fenfluramine + cannabidiol

**Fenfluramine + cannabidiol** refers to a combination of two pharmaceuticals, both approved as adjunctive treatments for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome but are used separately, not as a fixed combination product. **Fenfluramine** is a serotonergic agent that increases extracellular serotonin and modulates neurotransmission. Its anti-seizure efficacy in pharmacoresistant epilepsies such as Dravet syndrome is predominantly attributed to serotonin release and 5-HT2 receptor agonism, with additional sigma-1 receptor antagonist activity. **Cannabidiol** is a purified derivative of Cannabis sativa, and, while its precise anti-seizure mechanism remains incompletely defined, it likely involves modulation of multiple neural pathways excluding direct CB1/CB2 receptor activity. Both agents have been shown effective as add-on therapies for reducing convulsive seizures in Dravet and Lennox-Gastaut syndromes[1][3][5].